BioLamina

What BioLamina does

BioLamina AB is a privately held Swedish biotechnology company founded in 2009 in Sundbyberg, Sweden, that develops and manufactures full-length human recombinant laminin proteins marketed under the Biolaminin® brand. Its core products are chemically defined, animal-origin-free extracellular matrix substrates used to culture primary cells, pluripotent stem cells, and iPSC-derived cell types across 2D and 3D formats. The portfolio spans three regulatory tiers: LN (research grade), MX (translational research grade), and CTG (Cell Therapy Grade, with quality documentation suitable for ATMP manufacturing); product breadth covers at least ten tissue-specific laminin isoforms (e.g., LN521 for PSCs, LN111 for hepatocytes, LN211/221 for muscle/cardiac, LN332 for epithelial, LN411 for pancreas/vascular, LN421 for endothelial/kidney). The company also sells Biosilk, a recombinant spider silk 3D scaffold that can be biofunctionalized with Biolaminin isoforms for organoid culture. Scientific credibility is anchored in 428+ peer-reviewed publications and 31+ clinical journeys acknowledged by regulatory agencies including the FDA.

BioLamina operates a hybrid go-to-market combining self-service e-commerce for research-grade SKUs, a direct sales team for enterprise and large-quantity orders (including a wholly owned US subsidiary, BioLamina Inc., in Cambridge, MA), and an actively expanding global distributor network. Pricing is quote-based for large orders; shipments are ExWorks (Incoterms 2020). The company is funded by a €17M equity round in September 2023 led by Lauxera Capital Partners (with Bure Equity, Northislet, and founders) and a €20M EIB venture debt facility in April 2026; ownership is concentrated with Bure Growth (51.7%), Lauxera (16.2%), the Tryggvason family (15.3%), and Northislet (14.3%). Approximately 100 employees as of September 2025 serve academic researchers, biotech and cell therapy developers, and pharmaceutical organizations globally, with target indications including type 1 diabetes, Parkinson's disease, heart failure, acute liver failure, and cancer.

The business model is a one-time unit-pricing sale of consumable reagents, supplemented by grant-funded collaborative research (more than one-third of product development is publicly funded, with BioLamina acting as lead project manager on half of these collaborations). Recent strategic moves include the CEO transition to Klaus Langhoff-Roos (August 2024) and CTO Brian Hawkins (March 2025), alongside three new channel and co-development partnerships in late 2025 and 2026 (Cell X Technologies, Pluristyx, Cytochroma) that embed Biolaminin reagents into automated iPSC manufacturing workflows and downstream drug-discovery cell products.

Name

BioLamina

Legal name

BioLamina AB

Website

https://biolamina.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

BioLamina is a Swedish biotechnology company that develops and sells full-length human recombinant laminin proteins (Biolaminin®) and recombinant spider silk scaffolds for primary cell, stem cell, and iPSC-derived cell culture, serving academic researchers, biotech, and pharmaceutical organizations globally across research and clinical-grade applications.

Ownership category

akta.pro rank

Product category

Cell Culture Reagents

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), 3D Bioprinting & Biofabrication (HLAAAGAC), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Recombinant laminin proteins
• Cell culture substrates
• Stem cell matrices
• Cell therapy reagents
• 3D cell culture scaffolds

Headquarters

HQ city

Sundbyberg

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Biolaminin product sales: Sale of full-length human recombinant laminin proteins (Biolaminin®) across three product grades: LN (research grade), MX (translational research grade), and CTG (cell therapy grade). Products are sold via e-commerce webstore and direct sales. Pricing is quote-based for large orders.
2. Biosilk product sales: Sale of Biosilk and Biosilk 521 recombinant 3D culture scaffolds for organoid and 3D cell culture applications.
3. Collaborative research and grant funding: More than one-third of product development projects are publicly funded via grants. BioLamina serves as lead project manager for half of these collaborations. Grants support collaborative projects with academic and industry partners.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

BioLamina develops and manufactures full-length human recombinant laminin proteins (Biolaminin®) for 2D and 3D cell culture applications, offering 10+ tissue-specific isoforms across research (LN), translational research (MX), and Cell Therapy Grade (CTG) tiers for stem cell expansion, lineage differentiation, and GMP-compliant cell therapy manufacturing. The company also produces Biosilk, a recombinant spider silk scaffold for organoid and 3D culture, with Biosilk 521 combining the scaffold with Biolaminin 521 for pluripotent stem cell niches.

Product overview

BioLamina offers an expansive portfolio of full-length human recombinant laminin proteins under the Biolaminin® brand, designed for a variety of cell culture applications in both 2D and 3D formats. The product portfolio is organized across three tiers: LN (research grade) for basic research, MX (translational research grade) for research progressing toward clinical applications, and CTG (Cell Therapy Grade) for clinical use. Key products include Biolaminin 521 (LN521, MX521, CT521) for pluripotent stem cells, alongside tissue-specific isoforms such as LN111 (liver/epithelial), LN211/LN221 (muscle/cardiac), LN332 (epithelial), LN411 (pancreas/vascular/hematopoietic), LN421 (endothelial/kidney), and LN511 (mouse ESCs). The company also offers Biosilk and Biosilk 521 as 3D culture substrates—recombinant spider silk matrices that can be functionalized with Biolaminin isoforms for organoid formation. Biolaminin products are chemically defined, animal-origin-free, and support applications ranging from basic research to GMP-compliant cell therapy manufacturing across major regulatory jurisdictions.

Differentiator

Problem solved

Functional benefit

Brands

• Biolaminin: Full-length human recombinant laminin protein product line for cell culture applications, including research grade (LN), translational research grade (MX), and cell therapy grade (CTG) products.
• Biosilk

Products and services

• Biolaminin 521 LN (LN521) Full-length human recombinant laminin-521 substrate for pluripotent stem cells (ESCs and iPSCs). The natural laminin for human PSCs, supporting self-renewal under defined, animal-origin-free conditions and enabling single-cell passaging without apoptosis inhibitors such as ROCK inhibitor. Research-grade (LN) product.
• Biolaminin 521 MX (MX521) Full-length laminin-521 substrate designed for research aiming for clinical applications. Translational research grade (MX) supporting large-scale production and regulatory compliance. Chemically defined, batch-to-batch consistent, and animal-origin-free to the secondary level.
• Biolaminin 521 CTG (CT521) Full-length laminin-521 substrate designed for clinical applications. Cell Therapy Grade (CTG) with the most extensive quality control and regulatory compliance for GMP-compliant cell therapy production. Chemically defined, batch-to-batch consistent, and animal-origin-free to the secondary level with comprehensive quality documentation including Certificate of Analysis.
• Biolaminin 511 LN (LN511) Full-length human recombinant laminin-511. The natural laminin for mouse embryonic stem cells, supporting sustained pluripotency without LIF. Also efficiently supports various human cell types including neural and hepatic lineages. Research-grade (LN) product.
• Biolaminin 111 LN (LN111) Full-length human recombinant laminin-111, an essential extracellular matrix component for many cell types in vivo. Particularly useful for liver cells and various epithelial cell types. Research-grade (LN) product.
• Biolaminin 121 LN (LN121) Full-length human laminin-121 protein used as a general attachment protein for many cell types in culture. Research-grade (LN) product.
• Biolaminin 211 LN (LN211) Full-length human recombinant laminin-211 supporting growth, survival, and differentiation of tissue-specific cell types including motor neurons, cardiac cells, and skeletal muscle cells. Research-grade (LN) product.
• Biolaminin 221 LN (LN221) Full-length human recombinant laminin-221 supporting growth, survival, and differentiation of tissue-specific cell types including cardiac cells and skeletal muscle cells. Research-grade (LN) product.
• Biolaminin 332 LN (LN332) Full-length human recombinant laminin-332 supporting cells in epithelial basement membranes located in several tissues. Research-grade (LN) product.
• Biolaminin 411 LN (LN411) Full-length human recombinant laminin-411 supporting diverse tissue cell types such as cells from the pancreas, vascular, immune, nervous, and hematopoietic systems. Research-grade (LN) product.
• Biolaminin 421 LN (LN421) Full-length human recombinant laminin-421 supporting several tissue-specific cell types such as endothelial and kidney cells. Research-grade (LN) product.
• Biosilk Recombinant spider silk protein that forms a fibrous 3D network mimicking natural extracellular matrices. Provides a versatile scaffold for 3D cell culture and tissue engineering with excellent biocompatibility and biodegradability. Can be biofunctionalized with tissue-specific Biolaminin isoforms for organoid formation.
• Biosilk 521 Recombinant 3D culture matrix biofunctionalized with Biolaminin 521 at 9 µg/mL concentration. Creates stem cell-relevant niches for pluripotent stem cells (PSCs) and progenitors in a 3D culture format for organoid and stem cell expansion applications.

Quantifiable outcome

• 2–7x more pluripotent stem cells over 10 days compared to fragmented laminins; cells survive single-cell passaging without ROCK inhibitor
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• CytochromacoreStrategic or Co-development Partner · 28 May 2026Strategic collaboration to incorporate BioLamina's full-length human recombinant laminin 521 into Cytochroma's iPSC-derived cell product offerings (hepatocytes and cardiomyocytes) for drug discovery and disease modelling. Cytochroma has used Biolaminin since 2017, making it one of BioLamina's longest-standing partners. The partnership aligns with FDA Modernization Act 2.0 and supports generation, recovery, and expansion of iPSC-derived cells. Joint marketing activities, scientific engagement, and conference collaborations planned throughout 2026.
• Organoid COMMONS (led by Pluristyx)minorStrategic or Co-development Partner · 2 December 2025Pluristyx announced the Organoid COMMONS consortium aimed at establishing global standards for organoid development to support drug discovery and regulatory acceptance. The initiative involves ten industry partners seeking to replace traditional animal testing with human-relevant organoid models. While BioLamina is not explicitly named as a consortium partner in the source material, Pluristyx is a strategic partner of BioLamina.
• Cell X TechnologiescoreTechnology or Integration · 29 September 2025Collaboration to integrate BioLamina's defined laminin reagents (Biolaminin® LN521 and LN511, including GMP-compatible formulations) with Cell X's Celligent™ automation platform. Partnership aims to reduce operator-dependent variability and enhance reproducibility in advanced therapy manufacturing. Combines walk-away automation and imaging with high-quality laminin reagents to deliver scalable, GMP-compliant workflows for next-generation iPSC-based cell therapies.
• PluristyxcoreStrategic or Co-development Partner · 4 September 2025Strategic partnership to accelerate development of stem cell-based therapies. BioLamina products (including Biolaminin 521 LN) are integrated into Pluristyx's product platform. BioLamina's products were also featured in Pluristyx's PluriKit launched December 2024. The partnership combines Pluristyx's gene-modified iPSC platform with BioLamina's laminin reagents for next-generation cell therapy manufacturing.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Corning Incorporated: Corning Life Sciences is the dominant incumbent in cell culture substrates via Matrigel (its primary competing ECM product) and a broad portfolio of media, vessels, and surface treatments. Comparable as the incumbent alternative to BioLamina's recombinant laminins, particularly in research-grade stem cell culture.
• Thermo Fisher Scientific: Thermo Fisher offers CellMatrix, vitronectin-based substrates (e.g., rhVTN-N), and the full Gibco cell culture portfolio. Comparable as a broad incumbent that bundles substrates with media, cells, and instruments—directly competing with BioLamina's research and translational product tiers.
• Merck KGaA (Millipore Sigma): Millipore Sigma supplies human recombinant laminins (fragmented forms such as LM521), cell culture media, and GMP-grade manufacturing reagents. Comparable as an incumbent with overlapping laminin offerings and a much broader portfolio that competes head-to-head with BioLamina in both research and clinical-grade applications.
• Bio-Techne: Bio-Techne (R&D Systems, Tocris, ProteinSimple) supplies recombinant proteins, including laminins, as well as media, small molecules, and analytical tools for stem cell and cell therapy workflows. Comparable as a direct competitor in research-grade cell culture reagents with established distribution in academic and biotech channels.
• FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific supplies defined cell culture media and reagents for cell therapy manufacturing (including PRIME-XV and related lines) and competes directly with Biolaminin CTG products in GMP-compatible stem cell workflows. Comparable as an incumbent in clinical-grade cell therapy manufacturing consumables.
• Lonza Group: Lonza offers cell therapy manufacturing services, media (e.g., TheraPEAK, L7 media), and a range of ancillary materials for iPSC and cell therapy workflows. Comparable as an incumbent in clinical-grade cell therapy reagents and CDMO services, often partnered with or competing against BioLamina's CTG products.

Direct peers

• STEMCELL Technologies: STEMCELL Technologies is a leading specialized supplier of cell culture media, substrates, and tools for stem cell, immunology, and cell therapy research. Directly comparable as a specialized cell culture reagents vendor with overlapping customer base (academic researchers, biotech, and cell therapy developers) and similar product-led growth motion.
• CellGenix: CellGenix is a specialized supplier of GMP-grade raw materials and ancillary materials for cell therapy, gene therapy, and tissue engineering manufacturing. Directly comparable as a niche GMP-focused competitor to BioLamina's CTG laminin products in cell therapy manufacturing supply chains.
• Pluristyx:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/biolamina
• LinkedInlinkedin.com/company/biolamina-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioLamina